94 related articles for article (PubMed ID: 27334915)
1. Human epidermal growth factor receptor 2 status of breast cancer patients in Asia: Results from a large, multicountry study.
Pathmanathan N; Geng JS; Li W; Nie X; Veloso J; Hill J; McCloud P; Bilous M
Asia Pac J Clin Oncol; 2016 Dec; 12(4):369-379. PubMed ID: 27334915
[TBL] [Abstract][Full Text] [Related]
2. Human epidermal growth factor receptor 2 status of gastric cancer patients in Asia: results from a large, multicountry study.
Pathmanathan N; Geng JS; Li W; Nie X; Veloso J; Wang J; Hill J; Mccloud P; Bilous M
Asia Pac J Clin Oncol; 2017 Jun; 13(3):249-260. PubMed ID: 28008715
[TBL] [Abstract][Full Text] [Related]
3. Characteristics and treatment of human epidermal growth factor receptor 2 positive breast cancer: 43,485 cases from the National Cancer Database treated in 2010 and 2011.
Killelea BK; Chagpar AB; Horowitz NR; Lannin DR
Am J Surg; 2017 Feb; 213(2):426-432. PubMed ID: 27769548
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of equivocal human epidermal growth factor receptor 2 results and clinical utility of alternative chromosome 17 genes in patients with invasive breast cancer: A cohort study.
Sneige N; Hess KR; Multani AS; Gong Y; Ibrahim NK
Cancer; 2017 Apr; 123(7):1115-1123. PubMed ID: 27893937
[TBL] [Abstract][Full Text] [Related]
5. Limited human epidermal growth factor receptor 2 discordance in metastatic breast cancer patients treated with trastuzumab, a population based study.
van Rooijen JM; de Munck L; de Graaf JC; Siesling S; de Vries EG; Boers JE
Eur J Cancer; 2014 Mar; 50(5):885-91. PubMed ID: 24491395
[TBL] [Abstract][Full Text] [Related]
6. Change in Pattern of HER2 Fluorescent in Situ Hybridization (FISH) Results in Breast Cancers Submitted for FISH Testing: Experience of a Reference Laboratory Using US Food and Drug Administration Criteria and American Society of Clinical Oncology and College of American Pathologists Guidelines.
Shah MV; Wiktor AE; Meyer RG; Tenner KS; Ballman KV; Green SJ; Sukov WR; Ketterling RP; Perez EA; Jenkins RB
J Clin Oncol; 2016 Oct; 34(29):3502-3510. PubMed ID: 27458302
[TBL] [Abstract][Full Text] [Related]
7. Reflex Repeat HER2 Testing of Grade 3 Breast Carcinoma at Excision Using Immunohistochemistry and In Situ Analysis: Frequency of HER2 Discordance and Utility of Core Needle Biopsy Parameters to Refine Case Selection.
Prendeville S; Feeley L; Bennett MW; O'Connell F; Browne TJ
Am J Clin Pathol; 2016 Jan; 145(1):75-80. PubMed ID: 26712873
[TBL] [Abstract][Full Text] [Related]
8. Impact of Modified 2013 ASCO/CAP Guidelines on HER2 Testing in Breast Cancer. One Year Experience.
Varga Z; Noske A
PLoS One; 2015; 10(10):e0140652. PubMed ID: 26473483
[TBL] [Abstract][Full Text] [Related]
9. Associations of parity-related reproductive histories with ER± and HER2± receptor-specific breast cancer aetiology.
Anderson WF; Pfeiffer RM; Wohlfahrt J; Ejlertsen B; Jensen MB; Kroman N
Int J Epidemiol; 2017 Feb; 46(1):86-95. PubMed ID: 27818374
[TBL] [Abstract][Full Text] [Related]
10. Comparison of breast cancer in Indonesia and Malaysia--a clinico-pathological study between Dharmais Cancer Centre Jakarta and University Malaya Medical Centre, Kuala Lumpur.
Ng CH; Pathy NB; Taib NA; Teh YC; Mun KS; Amiruddin A; Evlina S; Rhodes A; Yip CH
Asian Pac J Cancer Prev; 2011; 12(11):2943-6. PubMed ID: 22393968
[TBL] [Abstract][Full Text] [Related]
11. Updated 2013 College of American Pathologists/American Society of Clinical Oncology (CAP/ASCO) guideline recommendations for human epidermal growth factor receptor 2 (HER2) fluorescent in situ hybridization (FISH) testing increase HER2 positive and HER2 equivocal breast cancer cases; retrospective study of HER2 FISH results of 836 invasive breast cancers.
Singh K; Tantravahi U; Lomme MM; Pasquariello T; Steinhoff M; Sung CJ
Breast Cancer Res Treat; 2016 Jun; 157(3):405-11. PubMed ID: 27180259
[TBL] [Abstract][Full Text] [Related]
12. HER2 FISH classification of equivocal HER2 IHC breast cancers with use of the 2013 ASCO/CAP practice guideline.
Fan YS; Casas CE; Peng J; Watkins M; Fan L; Chapman J; Ikpatt OF; Gomez C; Zhao W; Reis IM
Breast Cancer Res Treat; 2016 Feb; 155(3):457-62. PubMed ID: 26895325
[TBL] [Abstract][Full Text] [Related]
13. HER2-positivity rates in breast cancer: no variation over time when clinicopathological features and testing are stable.
Beltjens F; Bertaut A; Pigeonnat S; Loustalot C; Desmoulins I; Charon-Barra C; Coudert B; Fumoleau P; Arveux P; Arnould L
Eur J Cancer Care (Engl); 2017 Mar; 26(2):. PubMed ID: 26503126
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
[TBL] [Abstract][Full Text] [Related]
15. Comparison of immunohistochemistry with fluorescence in situ hybridization in determining the human epidermal growth factor receptor 2 status of breast cancer specimens: a multicenter study of 3,149 Chinese patients.
Han X; Shi Y; Ma L; Lyu Z; Yang H; Yao J; Li J; Li B; Qin Y
Chin Med J (Engl); 2014; 127(2):246-53. PubMed ID: 24438611
[TBL] [Abstract][Full Text] [Related]
16. Impact of the 2013 American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 (HER2) testing of invasive breast carcinoma: a focus on tumours assessed as 'equivocal' for HER2 gene amplification by fluorescence in-situ hybridization.
Bethune GC; Veldhuijzen van Zanten D; MacIntosh RF; Rayson D; Younis T; Thompson K; Barnes PJ
Histopathology; 2015 Dec; 67(6):880-7. PubMed ID: 25913507
[TBL] [Abstract][Full Text] [Related]
17. Human epidermal growth factor receptor 2 testing in invasive breast cancer: should histological grade, type and oestrogen receptor status influence the decision to repeat testing?
Rakha EA; Pigera M; Shin SJ; D'Alfonso T; Ellis IO; Lee AH
Histopathology; 2016 Jul; 69(1):20-4. PubMed ID: 26542743
[TBL] [Abstract][Full Text] [Related]
18. Analysis of molecular subtypes for the increased HER2 equivocal cases caused by application of the updated 2013 ASCO/CAP HER2 testing guidelines in breast cancer.
Guo L; Yuan P; Zhang J; Ling Y; Li W; Zhao B; Ying J; Xuan L
Breast Cancer Res Treat; 2017 Nov; 166(1):77-84. PubMed ID: 28712009
[TBL] [Abstract][Full Text] [Related]
19. Bcl-2 is a highly significant prognostic marker of hormone-receptor-positive, human epidermal growth factor receptor-2-negative breast cancer.
Seong MK; Lee JY; Byeon J; Sohn YJ; Seol H; Lee JK; Kim EK; Kim HA; Noh WC
Breast Cancer Res Treat; 2015 Feb; 150(1):141-8. PubMed ID: 25682076
[TBL] [Abstract][Full Text] [Related]
20. Basal-like immunophenotype markers and prognosis in early breast cancer.
Cassol L; Silveira Graudenz M; Zelmanowicz A; Cancela A; Werutsky G; Rovere RK; Garicochea B
Tumori; 2010; 96(6):966-70. PubMed ID: 21388060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
